This is an old revision of this page, as edited by Jfdwolff (talk | contribs) at 23:16, 17 June 2004 (tyop). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 23:16, 17 June 2004 by Jfdwolff (talk | contribs) (tyop)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)Olanzapine (Zyprexa® or in a combination with fluoxetine as Symbyax®) is one of the most commonly used atypical antipsychotics. Olanzapine has been FDA approved for the treatment of schizophrenia, acute mania in bipolar disorder, and as maintenance treatment in bipolar disorder. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company.
In December 2003 the FDA approved Symbyax to treat the depressive phase of bipolar disorder.
Uses
Since the ascendancy of atypical antipsychotics, olanzapine has become a frequently-used first line agent for acute psychosis and schizophrenia.
Side effects
Common side effects include extrapyramidal symptoms: muscle rigidity, stiffness and twitches, restlessness and sedation. Weight gain, obesity and diabetes mellitus are longer-term concerns that may affect the development of cardiovascular disease later on in life.
Olanzapine is reported to cause tardive dyskinesia and neurological malignant syndrome, although at a much reduced rate when compared to the classical antipsychotics.
External links
- Zyprexa - manufacturer's site
- Olanzapine.com - promotional site